BOTHELL, Wash., Feb. 12, 2026 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces it has entered into a multi-year supply agreement with Qkine Limited under which BioLife will distribute certain cytokine and growth factor products manufactured by Qkine for use in cell and gene therapy manufacturing.

The agreement provides BioLife with exclusive worldwide distribution rights to specific Qkine products for the CGT market and non-exclusive rights to Qkine products in the CGT market. In addition, the companies intend to collaborate on a process development and validation program to enable Qkine to package certain of its products using BioLife's proprietary CellSeal^® Connect vial system, which is designed to be incorporated into closed system and/or automated CGT workflows.

Roderick de Greef, BioLife's Chairman and CEO, commented, "We are pleased to establish this strategic distribution and CellSeal^® Connect product development relationship with Qkine, a recognized leader in the fast-growing cytokines market. Qkine's cytokine products are highly complementary to our cell culture supplement offerings and expand the portfolio of solutions we offer our CGT customers. We have specifically identified cytokines along with other biologically active cell culture media components as attractive, fast-growing and profitable adjacent product categories that align with our long-term growth strategy."

Dr. Robert Scoffin, Qkine's CEO, added "We are excited to partner with BioLife, a well-respected leader in the bioprocessing tools market. This collaboration brings together our expertise in cytokine innovation with BioLife's extensive reach and customer relationships in the CGT market. Together, we aim to deliver greater value to customers and help advance the development and manufacture of next‑generation cell and gene therapies."

Cytokines and growth factors play a vital role in the manufacturing of cell and gene therapies by regulating and stimulating cell growth, activation and performance. According to third-party market research, the current global cytokines market is estimated at $500 million annually and is projected to grow at a mid-teens compound annual rate, reaching $1 billion by 2030, driven by expanding CGT development pipelines.

About Qkine Limited
With headquarters in Cambridge, England, Qkine Limited is dedicated to advancing stem cell and regenerative medicine research by developing high-purity, bioactive growth factors and cytokines. With a focus on scientific rigour and product excellence, Qkine supports cutting-edge biological research and clinical translation worldwide. For more information, please visit www.qkine.com.

About BioLife Solutions
BioLife Solutions is a leading developer and supplier of bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets. Our expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. For more information, please visit www.biolifesolutions.com or follow BioLife on LinkedIn and X.

Cautions Regarding Forward Looking Statements

Certain statements contained in this press release are not historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "plans," "expects," "believes," "anticipates," "designed," "may," "estimate," "guidance," and similar words are intended to identify forward-looking statements. Forward-looking statements are based on our current expectations and beliefs, and involve a number of risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those stated or implied by the forward-looking statements. A description of certain of these risks, uncertainties and other matters can be found in filings we make with the U.S. Securities and Exchange Commission, all of which are available at www.sec.gov. Because forward-looking statements involve risks and uncertainties, actual results and events may differ materially from results and events currently expected by us. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We undertake no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in its expectations with regard to these forward-looking statements or the occurrence of unanticipated events.

Media & Investor Relations

At the Company
Troy Wichterman
Chief Financial Officer
(425) 402-1400 
twichterman@biolifesolutions.com

Investors
Alliance Advisors IR
Jody Cain
(310) 691-7100
jcain@allianceadvisors.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/biolife-solutions-signs-multi-year-supply-agreement-with-qkine-limited-to-expand-its-product-portfolio-into-the-rapidly-growing-cytokines-market-302685840.html

SOURCE BioLife Solutions, Inc.